Seelaus Asset Management’s Jasper Therapeutics JSPR Stock Holding History

Seelaus Asset Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,554	Closed	-$453K	–	264
2021 Q2	$453K	Sell	4,554 -50	-1%	-$4.97K	0.26%	127
2021 Q1	$456K	Buy	4,604 +3,042	+195%	+$309K	0.29%	107
2020 Q4	$156K	Buy	+1,562	New	+$155K	0.11%	178

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Seelaus Asset Management's JSPR Position: Q3 2021 in Review

Seelaus Asset Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 4,554 shares — an estimated $453K sold.

Seelaus Asset Management first reported a position in JSPR in Q4 2020 and held it in 3 quarters. The position peaked at $456K in Q1 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Seelaus Asset Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Seelaus Asset Management sold 4,554 Jasper Therapeutics shares in Q3 2021, an estimated $453K.
Seelaus Asset Management first reported a position in Jasper Therapeutics in Q4 2020 and held it in 3 quarters.
Seelaus Asset Management's Jasper Therapeutics position peaked at $456K in Q1 2021.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Seelaus Asset Management's 13F filing for Q3 2021, filed 19 Oct 2021.